Full Press Release Details
BridgeBio Pharma's QED Therapeutics And Helsinn Group Announce FDA Approval Of TRUSELTIQ (infigratinib) For Patients With Cholangiocarcinoma.
BBIO
BridgeBio Pharma's QED Therapeutics And Helsinn Group Announce FDA Approval Of TRUSELTIQ (infigratinib) For Patients With Cholangiocarcinoma
Key Takeaway: BridgeBio Pharma's QED Therapeutics And Helsinn Group Announce FDA Approval Of TRUSELTIQ (infigratinib) For Patients With Cholangiocarcinoma